11:15 AM
Mar 07, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Breast cancer

Cell culture studies suggest inhibiting NEK9 or MAP2K4 could help treat PI3K inhibitor-resistant triple-negative breast cancer (TNBC). In tumor samples from patient-derived xenograft (PDX) mouse models of TNBC, levels of NEK9 and MAP2K4 were higher in tumors resistant to the PI3K...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD